Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027

Allogene Therapeutics, Inc.

Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.
Cash & investments $373.1M; cash runway into 2H 2026; 2025 guidance: ~$170M cash burn.
ALPHA3 pivotal trial for cema-cel in 1L LBCL: 40 sites activated; futility analysis mid-2025; primary EFS data YE2026.
ALLO-329 autoimmune: IND cleared; RESOLUTION basket trial start mid-2025; proof-of-concept data YE2025.
ALLO-316 RCC: Phase 1b expansion fully enrolled; data mid-2025; RMAT designation received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.